MGMT and neoplasm: While MGMT methylation status is the single prognostic and predictive marker with MGMT-methylated patients having superior response to systemic management, improved progression, and overall survival [4], and IDH mutation status has redefined GB classification with IDH-mutated tumors now reclassified given superior outcome [5], both molecular features are detected in tumor tissue.